NCT05062954Completed
Effects of a Polyphenol-rich Cranberry Extract on Cardiometabolic and Neurocognitive Health
Effects of a Polyphenol-rich Cranberry Extract on Cardiometabolic and Neurocognitive Health in Individuals With Abdominal Obesity: a Double-blind Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
The objective of this double-blind, parallel, randomized placebo-controlled clinical trial is to evaluate the effects of consumption of polyphenol-rich cranberry extract standardized in PACs (36 mg PACs/capsule) on cardiometabolic and neurocognitive health in women and men presenting abdominal obesity over an 8-week intervention period. The study will be conducted at Quebec Heart and Lung Institute - Laval University. The study will involve a total of 60 adult men and women presenting abdominal obesity. Included participants will be randomly assigned to the consumption of a cranberry extract or a placebo at a rate of one capsule per day for 8 weeks (56 days). The main outcomes are changes in metabolic profile, neurocognitive performance as well as brain structure and function following polyphenol-rich cranberry extract standardized in PACs compared with the placebo.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 49 (actual)
- First submitted
- 31 Aug 2021
- Start date
- 21 Oct 2021
- Primary completion date
- 9 Jan 2025
- Lead sponsor
- Laval University
- Diseases
- Obesity
- NCT number
- NCT05062954
What you commit to
- Study type: Interventional
- Participants enrolled: 49
- From 21 Oct 2021 to the primary completion date, 9 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medication for dyslipidemias, CVD, T2D or obesity;
- Medication that may affect the CNS;
- Anticoagulant/blood thinning medication in the last month;
Other illness
- Any severe uncontrolled medical, surgical, neurological or psychiatric condition;
- Gastro-intestinal conditions or disorders likely to impact on absorption;
- History of nephrolithiasis or urolithiasis;
- Contraindications to MRI (cardiac pacemaker/defibrillator, cochlear implant or other ear implant, implanted insulin pump or other infusion pump systems, neurostimulator or other electronic/magnetic implant or device, any type of prothesis, aneurysm clips, any metallic fragments, vascular access port, catheter, dental retainer, claustrophobia, surgery in the last 3 months);
- Known allergy or intolerance to cranberry;
Other
- Pregnant or breastfeeding women;
- Substance or alcohol abuse;
- Currently smoking.
Who the study is looking for
- Men and women aged between 30-70 years old;
- BMI equal or greater than 25 kg/m2;
- Waist circumference ≥85 cm for women, ≥90 cm for men;
- Stable weight in the past 3 months;
- Plasma triglycerides levels ≥1.5 mmol/L for men and women;
- Access to a computer and Internet.
Age in the registry: 30 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Quebec Heart and Lung Institute - Laval University Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.